[Determination of serum pepsinogen I and II for assessment of gastroduodenal tolerance of S(+) ibuprofen].
Therapy with non-steroidal anti-inflammatory drugs often causes gastroduodenal side effects. Changes in the gastric mucosa were studied by determination of serum pepsinogen I and pepsinogen II by the means of radioimmunoassay. 41 patients with degenerative rheumatic diseases were divided into two groups, 21 patients receiving 600 mg S(+) ibuprofen daily (3 x 200mg) and 20 patients receiving 900 mg S(+) ibuprofen daily (3 x 300 mg) over a 14-day period. No significant increase occurred in mean and median values of pepsinogen I and II. Indeed, no changes in serum pepsinogen I and II were noted in 80% of the patients in the higher dosage group and in more than 90% of the lower dosage group. None of the gastroduodenal side effects frequently reported during therapy with non-steroidal anti-rheumatic drugs occurred.
Kullich
W
W
Ludwig-Boltzmann-Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Wallner
H
H
Klein
G
G
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*; D010437:Peptic Ulcer / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D012307:Risk Factors; D013237:Stereoisomerism
D010435:Pepsinogens; D007052:Ibuprofen
Die Bestimmung von Serumpepsinogen I und II zur Beurteilung der gastroduodenalen Verträglichkeit von S(+)-Ibuprofen.